SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: Secondary bacterial pneumonia and viral co-infections

Sharov, Konstantin S.

doi:10.7189/jogh.10.020504

Cited by 43 publications

(48 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Later milder symptomatic patients were included in the tests too. But only since May and especially in summer 2020, a broad and much more representative cohort of European population commenced to be tested [66] , [67] , [68] , [69] , [70] . Using the May and June data as input parameters for the model enabled us to augment its quality and predicting force.…”

Section: Resultsmentioning

confidence: 99%

Creating and applying SIR modified compartmental model for calculation of COVID-19 lockdown efficiency

Sharov

2020

Chaos, Solitons & Fractals

View full text Add to dashboard Cite

Highlights SIR compartmental model of COVID-19 spread may help to evaluate efficiency of lockdown measures. Epidemiological data collected in fifteen european countries, are taken as input parameters. Herd immunity level and the time of its formation are considered as factors indicating efficiency of lockdowns. Lockdown and no-lockdown mode of containment lead to roughly similar results. Lockdowns do not stop COVID-19 spread. Rationale for lockdowns is avoidance of healthcare system overburdening. Reliance on lockdowns as the only administrative measures that may contain a pandemic, is a misstep that should be avoided in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

Creating and applying SIR modified compartmental model for calculation of COVID-19 lockdown efficiency

Sharov

2020

Chaos, Solitons & Fractals

View full text Add to dashboard Cite

show abstract

“…Pneumonia caused by viral infections usually has secondary bacterial infection 22 . COVID-19 may also be associated with secondary bacterial infections 23 , 24 . Now, the demonstrated antiviral activity to HCoVs, including SARS-CoV-2, as well as the preferential distribution in lungs via oral administration warranted the clinical trials of carrimycin for the treatment of COVID-19 in China (ChiCTR2000029867 and ChiCTR2000032242).…”

Section: Discussionmentioning

confidence: 99%

Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2

Yan

Sun

Wang

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

COVID-19 pandemic caused by SARS-CoV-2 infection severely threatens global health and economic development. No effective antiviral drug is currently available to treat COVID-19 and any other human coronavirus infections. We report herein that a CFDA-approved macrolide antibiotic, carrimycin, potently inhibited the cytopathic effects (CPE) and reduced the levels of viral protein and RNA in multiple cell types infected by human coronavirus 229E, OC43, and SARS-CoV-2. Time-of-addition and pseudotype virus infection studies indicated that carrimycin inhibited one or multiple post-entry replication events of human coronavirus infection. In support of this notion, metabolic labelling studies showed that carrimycin significantly inhibited the synthesis of viral RNA. Our studies thus strongly suggest that carrimycin is an antiviral agent against a broad-spectrum of human coronaviruses and its therapeutic efficacy to COVID-19 is currently under clinical investigation.

show abstract

“…The full search output is available as Supplementary Material S3. After the exclusion of duplicates and not relevant records, twenty studies were included in the systematic review and metaanalysis, for a total of 2611 patients with COVID-19 who developed at least one episode of VAP [9,[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. The process of inclusion and exclusion is detailed in the PRISMA flow diagram, provided in Figure 1.…”

Section: Characteristics Of Included Studies and Patientsmentioning

confidence: 99%

Ventilator-Associated Pneumonia in Patients with COVID-19: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

The aim of this systematic review and meta-analysis was to estimate the pooled occurrence of ventilator-associated pneumonia (VAP) among patients admitted to an intensive care unit with COVID-19 and mortality of those who developed VAP. We performed a systematic search on PubMed, EMBASE and Web of Science from inception to 2nd March 2021 for nonrandomized studies specifically addressing VAP in adult patients with COVID-19 and reporting data on at least one primary outcome of interest. Random effect single-arm meta-analysis was performed for the occurrence of VAP and mortality (at the longest follow up) and ICU length of stay. Twenty studies were included in the systematic review and meta-analysis, for a total of 2611 patients with at least one episode of VAP. The pooled estimated occurrence of VAP was of 45.4% (95% C.I. 37.8–53.2%; 2611/5593 patients; I2 = 96%). The pooled estimated occurrence of mortality was 42.7% (95% C.I. 34–51.7%; 371/946 patients; I2 = 82%). The estimated summary estimated metric mean ICU LOS was 28.58 days (95% C.I. 21.4–35.8; I2 = 98%). Sensitivity analysis showed that patients with COVID-19 may have a higher risk of developing VAP than patients without COVID-19 (OR 3.24; 95% C.I. 2.2–4.7; P = 0.015; I2 = 67.7%; five studies with a comparison group).

show abstract

SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: Secondary bacterial pneumonia and viral co-infections

Cited by 43 publications

References 58 publications

Creating and applying SIR modified compartmental model for calculation of COVID-19 lockdown efficiency

Creating and applying SIR modified compartmental model for calculation of COVID-19 lockdown efficiency

Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2

Ventilator-Associated Pneumonia in Patients with COVID-19: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About